Navigation Links
Echo Therapeutics, Inc. Announces 2014 Financial Results

ISELIN, N.J., April 15, 2015 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on non-invasive continuous glucose monitoring and associated technologies, today announced financial results for the year ended December 31, 2014.  Echo's Annual Report on Form 10-K, as filed with the SEC, will be available by visiting the Investors section of Echo's website at on April 15, 2015 after the close of the financial markets.

Fiscal Year 2014 Financial ResultsFor fiscal year 2014, the Company was principally involved with the product development and clinical studies of its continuous glucose monitoring system. Echo's net loss for fiscal year 2014 was $15.3 million, or ($1.24) per share, compared to $19.4 million, or ($2.33) per share during 2013.  The operating loss for fiscal year 2014 was $12.3 million compared to $19.6 million for fiscal year 2013.  Research and development expenses were $5.0 million for fiscal year 2014 compared to $13.0 million for fiscal year 2013.  The decrease in research and development expenses was primarily related to the lack of financing that eventually led to a temporary shut down of operations in the fourth quarter of 2014.  Selling, general and administrative expenses were $7.4 million during 2014 compared to $6.7 million in 2013.
The increase in selling, general and administrative expenses was primarily due to increased legal costs and expenses associated with the proxy fight that enveloped the Company in 2014.  Echo reported a cash balance of approximately $1.3 million as of December 31, 2014. 

Recent Corporate Highlights:

  • In March 2015, Echo achieved its wireless mobile communication milestone, making it possible for its continuous glucose sensor to transmit data to any mobile platform. The achievement marked the first key step in the strategic transformation of the Company's technology from a hospital-based medical system to a consumer product in both the wearable-health and diabetes segments.
  • In January 2015, Echo re-established its operational and strategic collaboration agreement with Medical Technologies Innovation Asia (MTIA), Ltd., Hong Kong. The partnership agreement includes a licensing and technology transfer under which MTIA will manufacture Echo's proprietary skin permeation and analyte measurement technology. Echo granted MTIA rights to develop, manufacture, market, and distribute Echo's technology on an exclusive basis for the Chinese market, including the Peoples' Republic of China, Hong Kong, Macau and Taiwan.
  • In January 2015, Echo rehired key members of its Research & Development team, led by Tom Bishop, Vice President of Operations and Product Development, to refine and adapt Echo's core technology for wearable technology and diabetes applications.
  • In December 2014, Scott W. Hollander was appointed Chief Executive Officer. Mr. Hollander has more than 20 years of experience in the medical device, pharmaceutical and capital equipment industries, and most recently served as Vice President, Business Development, Otsuka Pharmaceuticals as well as President and Chief Executive Officer of Interpharma-Praha, an Otsuka subsidiary company.
  • In December 2014, Alan W. Schoenbart, CPA, a senior executive with more than thirty years of financial management experience, joined the Company as Chief Financial Officer (CFO) from Hudson News Distributors, where he most recently served as the CFO. Mr. Schoenbart's prior experience included CFO for Forticell Bioscience, Inc., a publicly traded medical device company, and Audit Manager at KPMG.
  • In December 2014, pursuant to a Securities Purchase Agreement, Platinum Value Arbitrage Fund L.P. and certain other investors agreed to purchase shares of the Company's stock for an aggregate purchase price of $4 million. The agreement includes an upfront investment of $1 million, with the remaining portion of the investment to be made in monthly installments.
  • "Now that the events of 2014 are behind us, and we have rehired and refocused our Research & Development team and have achieved our mobile communication milestone, I am very excited about the potential of Echo's proprietary, non-invasive continuous glucose monitoring technology in the consumer space," said Scott W. Hollander, Echo's President and CEO. "With our new team, along with the cash infusion associated with the Securities Purchase Agreement, we are focused on the continued, accelerated pace of product development. I am committed to prudently utilizing our resources for the improvement of the technology and for business development activities."

    About Echo TherapeuticsEcho Therapeutics is developing its non-invasive, wireless, continuous glucose monitoring (CGM) system. A significant opportunity exists for the Company's CGM to be used in the fitness, weight loss and personal lifestyle wearable-health space. A longer-term opportunity also exists in the outpatient diabetes and hospital settings. Echo developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, and enhanced delivery of topical pharmaceuticals.

    Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's clinical studies, the safety and efficacy of Echo's CGM System, the failure of future development and preliminary marketing efforts related to Echo's CGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell Echo's CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its CGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2013, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

    For More Information:
    Christine H. Olimpio
    Director, Investor Relations and Corporate Communications
    (732) 549-0128Connect With Us:
    - Visit our website at
    - Follow us on Twitter at
    - Join us on Facebook at  Echo Therapeutics, Inc.Condensed Consolidated Balance Sheets  December 31,2014December 31,2013ASSETSCurrent Assets:Cash and cash equivalents

    $ 8,055,385Other current assets

    543,3121,319,713Total current assets

    1,822,2539,375,098Net property and equipment (including assets under capitalized leases)

    1,138,5931,495,807Other Assets:Intangible assets, net of accumulated amortization

    9,625,0009,625,000Deferred financing costs

    -2,581,324Other assets

    9,99012,066Total other assets

    9,634,99012,218,390Total assets

    LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payable

    Deferred revenue from licensing agreements

    -76,428Derivative warrant liability

    208,1551,119,155Accrued expenses and other liabilities

    968,3921,412,468Total current liabilities

    2,978,0163,644,371Deferred revenue from licensing arrangements, net of current portion

    95,53576,428Total liabilities

    3,073,5513,720,799Commitments and ContingenciesStockholders' Equity:Convertible preferred stock, Series C,D,E & F

    35,89927,496Common stock

    126,295117,764Additional paid-in capital

    137,292,157132,192,648Accumulated deficit

    (127,932,066)(112,969,412)Total stockholders' equity

    9,522,28519,368,496Total liabilities and stockholders' equity

    Condensed Consolidated Statements of OperationsYear EndedDecember 31,20142013Licensing revenue

    Operating Expenses:Research and development

    4,962,19612,991,502Selling, general and administrative

    7,415,0496,680,983Total operating expenses

    12,377,24519,672,485Loss from operations

    (12,319,924)(19,644,885)Other Income (Expense):Interest expense, net

    (3,550,504)(3,900,064)Other income

    1,88811,566Loss on disposals of assets

    (1,114)-Gain on revaluation of derivative warrant liability

    911,0004,465,986Other income (expense), net

    (2,638,730)577,488Net loss before taxes

    (14,958,654)(19,067,397)State income taxes

    4,000-Net loss

    (14,962,654)(19,067,397)Deemed dividend on beneficial conversion feature of convertible preferred stock

    (350,000)(371,140)Net loss applicable to common shareholders

    $   (15,312,654)$   (19,438,537)Net loss per common share, basic and diluted


    Basic and diluted weighted average common shares


    (Reflects 1-for-10 reverse stock split, effective June 7, 2013)

    SOURCE Echo Therapeutics, Inc.
    Copyright©2015 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
    2. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
    3. Signature Therapeutics, Inc., Presents Four Scientific Posters Today at PAINWeek 2013 Meeting
    4. Chrysalis BioTherapeutics, Inc., Receives $1.5m from the National Cancer Institute to Mitigate Radiotherapy-Induced Brain Tissue Damage
    5. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Osiris Therapeutics, Inc.
    6. Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics, Inc.
    7. Levi & Korsinsky, LLP Launches Investigation of SAREPTA THERAPEUTICS, INC. for Possible Violations of Federal Securities Laws
    8. Financial Results, Agreements, Meetings, and Clinical Trials - Research Report on Cell Therapeutics, Akorn, Ligand, Intercept Pharmaceuticals and Ariad Pharmaceuticals
    9. Inhibikase Therapeutics, Inc. Elects Anthony Zook To The Board Of Directors
    10. Potential Acquisitions and Stock Price Updates - Research Report on BioMarin, Covidien, United Therapeutics, Brookdale, and Seattle Genetics
    11. Dual Chamber Syringes & Injectors. Devices, Therapeutics, Markets and Forecasts
    Post Your Comments:
    (Date:3/20/2019)... ... 20, 2019 , ... Becker's Hospital Review is pleased to ... Pharmacy Conference, held May 2-4 at the Swissotel in Chicago. The celebrity keynotes ... Sunday and NFL Legend; ,     Bobbi Brown, Makeup Artist, Author, Entrepreneur ...
    (Date:3/20/2019)... ... March 20, 2019 , ... According to Prevent Blindness, ... of eye diseases such as cataract, glaucoma and age-related macular degeneration. Women ... related to pregnancy and menopause. , Prevent Blindness has designated April as Women’s Eye ...
    (Date:3/20/2019)... , ... March 20, 2019 , ... Nike Volleyball ... be directed by Rick Swan, the head volleyball coach at Colorado College. , This ... means that players from the Rocky Mountain area now have an opportunity to train ...
    Breaking Medicine Technology:
    (Date:3/20/2019)... ... March 20, 2019 , ... Santa Clara Family ... that the National Committee for Quality Assurance (NCQA) has awarded an Accreditation status ... a private, not-for-profit organization dedicated to improving health care quality by evaluating health ...
    (Date:3/20/2019)... ... 2019 , ... Many companies are developing anti-aging drugs using ... , A recent publication in the Journal of Stem Cell Research & Therapy ... promising results for the reversal of aging. The paper, entitled “Quest for Immortality ...
    (Date:3/20/2019)... MEDINA, Ohio (PRWEB) , ... March 20, 2019 ... ... Neck or back pain from disc herniation's, degenerative disc disease, spinal stenosis, ... treatment all in one location! , At Advanced Spine Joint and Wellness ...
    (Date:3/20/2019)... ... March 20, 2019 , ... Natreon has ... composition of trivalent chromium chloride combined with extracts of amla and shilajit, that ... granted patent, along with 7 clinical studies on Crominex®3+, establish this ingredient as ...
    (Date:3/20/2019)... ... March 20, 2019 , ... Nike Softball Camp ... Slupinski will be leading the camp with her staff. , Coach Slupinski takes the ... Redlands where she was the head coach for 2 seasons. Slupinski had an impressive ...
    Breaking Medicine News(10 mins):